You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Autism Treatment The Pivotal Skills Trainer

    SBC: ACCELERATIONS EDUCATIONAL SOFTWARE            Topic: N/A

    DESCRIPTION (provided by applicant): This STTR (Phase 1) project begins the translation of untapped scientific findings into an improved software tool for teaching children with autism spectrum disorders and other disabilities. The project evaluates a package to train teachers to use software called the Pivotal Skills Trainer and examines whether doing so improves preschoolers' functional communic ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  2. Autism Education and Treatment with PowerPoint Software

    SBC: ACCELERATIONS EDUCATIONAL SOFTWARE            Topic: N/A

    DESCRIPTION (provided by applicant): PowerPoint(R) multimedia software is ubiquitous in our schools but its capacity for teaching children with autism spectrum and related disorders barely has been realized. This STTR (Phase I) project will begin to change this state of affairs by researching and developing empirically derived multimedia teaching tools. Encouraged by early-stage feasibility work, ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  3. N/A

    SBC: ACCESS PHARMACEUTICALS, INC.            Topic: N/A

    N/A

    STTR Phase I 2000 Department of Health and Human ServicesNational Institutes of Health
  4. VALIDATION OF FLUORESCENT DEOXYGLUCOSE (2-NBDG) IN TUMORS

    SBC: 3GEN, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): A new fluorescent analogue of d-glucose, 2-[N-(7-nitrobenz-2-oxa-1,3-diaxol-4-yl)amino]-2- deoxyglucose (2-NBDG), was recently developed, but has not been characterized as a marker of glucose uptake in cancer cells. Validating this new tracer as a glucose analogue for optical imaging of superficial tumors may have a major impact on clinical and preclinical imag ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  5. Novel Inhibitors of Pim Protein Kinases

    SBC: Vortex Biotechnology Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): There is a growing body of evidence that implicates the protein kinase Pim-1 as a major driver of prostate cancer progression, and perhaps response to chemotherapy. Pim-1 is overexpressed in early prostate intraepithelial neoplasia and metastatic prostate cancer, and its levels predict response to therapy. Pim-1-overexpressing mouse prostate stem cells demonstr ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  6. Smart Membranes for Biomolecular Detection

    SBC: 20 20 Genesystems Inc            Topic: N/A

    DESCRIPTION (provided by applicant): The main objective of this project is to develop membranes with surfaces tailored for specific affinity for a particular protein or nucleic acid molecule. These 'smart' membranes will be used in the next generation of high throughput Layered Expression Scanning (LES) applications, such as tissue screening and analytical blotting (northern and western). The hear ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  7. Auto-antibody profiling of non-small cell lung cancer

    SBC: 20 20 Genesystems Inc            Topic: N/A

    DESCRIPTION (provided by applicant): Tumor markers, measured in peripheral blood, could assist in diagnosis and management of non-small cell lung cancer (NSCLC) and potentially improve historically dismal outcomes. Circulating antibodies, generated to a wide range of tumor-associated proteins, can be translated into a valuable blood test for lung cancer. Preliminary data supports this hypothesis. ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  8. Therapy for gastrointestinal disorders

    SBC: AGENNIX, INC.            Topic: N/A

    DESCRIPTION (Applicant's Abstract): The overall goal of this research proposal is to determine the effectiveness of recombinant human lactoferrin (rhLF) for treating gastrointestinal (GI) disorders. This Phase II proposal will focus on the ability of rhLF to treat the 01 side effects of non-steroidal anti-inflammatory drugs (NSAIDs), a class of drugs widely-us ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  9. Recombinant Lactoferrin and Necrotizing Enterocolitis

    SBC: AGENNIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This feasibility study is based on our hypothesis that recombinant human lactoferrin [rhLF] can prevent or reduce severity of necrotizing enterocolitis [NEC]. NEC is mainly a disease of very low birth weight [VLBW] human infants. It is a leading cause of morbidity and mortality in neonatal intensive care units, with incidence of approximately 10 percent in VLBW ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  10. Oral Formulation of Zonulin Antagonist AT-1001 for Diabe

    SBC: ALBA THERAPEUTICS CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): The trigger for autoimmune destruction of pancreatic beta cells in Type 1 diabetes (T1D) is unclear. Evidence exists for the role of increased intestinal permeability, secondary to intestinal tight junctions (tj) disassembly, in the pathogenesis of various autoimmune diseases including T1 D. Over the last decade our studies have focused on the mechanism(s) of a ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government